- Home
- TPST vs HCWB Comparison
TPST vs HCWB Comparison
Compare TPST & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- HCWB
- Stock Information
- Founded
- TPST 2011
- HCWB 2018
- Country
- TPST United States
- HCWB United States
- Employees
- TPST N/A
- HCWB N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- HCWB Health Care
- Exchange
- TPST Nasdaq
- HCWB Nasdaq
- Market Cap
- TPST 27.2M
- HCWB 26.6M
- IPO Year
- TPST N/A
- HCWB 2021
- Fundamental
- Price
- TPST $0.89
- HCWB $0.29
- Analyst Decision
- TPST Strong Buy
- HCWB
- Analyst Count
- TPST 4
- HCWB 0
- Target Price
- TPST $20.00
- HCWB N/A
- AVG Volume (30 Days)
- TPST 3.3M
- HCWB 98.1K
- Earning Date
- TPST 11-12-2024
- HCWB 11-14-2024
- Dividend Yield
- TPST N/A
- HCWB N/A
- EPS Growth
- TPST N/A
- HCWB N/A
- EPS
- TPST N/A
- HCWB N/A
- Revenue
- TPST N/A
- HCWB $3,495,990.00
- Revenue This Year
- TPST N/A
- HCWB N/A
- Revenue Next Year
- TPST N/A
- HCWB N/A
- P/E Ratio
- TPST N/A
- HCWB N/A
- Revenue Growth
- TPST N/A
- HCWB 22.27
- 52 Week Low
- TPST $0.83
- HCWB $0.28
- 52 Week High
- TPST $6.00
- HCWB $1.93
- Technical
- Relative Strength Index (RSI)
- TPST 34.45
- HCWB 24.86
- Support Level
- TPST $0.94
- HCWB $0.28
- Resistance Level
- TPST $1.16
- HCWB $0.50
- Average True Range (ATR)
- TPST 0.10
- HCWB 0.04
- MACD
- TPST 0.00
- HCWB -0.01
- Stochastic Oscillator
- TPST 15.50
- HCWB 7.38
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.